PDCD1 and neoplasm: Combination of Met@Man-MPs and anti-PD-1 antibody generated the strongest synergistic anticancer effects, achieving 75.0% tumor shrinkage (Supplementary Fig. 37b), 81.2% metastasis inhibition (Supplementary Fig. 37c, d) and longer survival time (Supplementary Fig. 37f).